Wijesingha, Naomi http://orcid.org/0000-0003-0206-1061
Sivaprasad, Sobha
Article History
Received: 20 October 2023
Revised: 15 November 2023
Accepted: 16 November 2023
First Online: 20 December 2023
Competing interests
: SS reported receiving financial support from AbbVie, Amgen, Apellis, Bayer, Biogen, Boehringer Ingelheim, Novartis, Eyebiotech, Eyepoint Pharmaceuticals, Janssen Pharmaceuticals, Nova Nordisk, Optos, Ocular Therapeutics, Kriya Therapeutics, OcuTerra, Roche, Stealth Biotherapeutics, Sanofi. SS is Editor in Chief of <i>Eye</i>. NW declares no conflict of interest.